amobarbital has been researched along with methylprednisolone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Berton, AM; Ghigo, E; Giordano, R; Grottoli, S; Prencipe, N | 1 |
3 other study(ies) available for amobarbital and methylprednisolone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Amobarbital; Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Treatment; Dextroamphetamine; Drug Combinations; Humans; Hypothalamo-Hypophyseal System; Methylprednisolone; Respiratory Distress Syndrome; Respiratory Insufficiency; SARS-CoV-2 | 2021 |